VC302 / Boryung Group, Therabest, ViGenCell - LARVOL DELTA

Triple-Engineered GD2 CAR iPSC-Derived NK Cells Incorporating IL15RF-Mediated Persistence, CXCR2-Driven Tumor Homing, and B2M Knockout for Enhanced Antitumor Activity in Glioblastoma (EACR 2026) - "VC302 achieves enhanced tumor trafficking, prolonged cellular persistence, and resistance to host T-cell–mediated clearance in vitro, while providing improved tumor control in an orthotopic GBM model. These findings support VC302 as a rationally engineered CAR-NK platform to overcome key biological barriers in GD2-positive glioblastoma."

IO biomarker • Brain Cancer • Glioblastoma • Oncology • Solid Tumor • B2M • CD8 • CXCL8 • CXCR2

Vigencell -Terravest Sign Joint Development Agreement for CAR-NK Cell Therapy [Google translation] (HIT News) - "Vigencell...announced on the 30th that it has signed a joint research and development agreement for the GD2 CAR-NK cell therapy 'TB-302' with Teravest, an iPSC-derived immune cell therapy company...Through this agreement, the two companies will jointly develop an off-the-shelf GD2 CAR-NK cell therapy for intractable solid cancers including glioblastoma. Vigencell plans to introduce TB-302, an iPSC-based CAR-NK therapy from Teravest, and pursue clinical development using it in the future....With this contract, Vigencell will pay a down payment of 3 billion won to Teravest and jointly conduct research and development by introducing TB-302 with the goal of treating intractable solid cancers including glioblastoma."

Licensing / partnership • Glioblastoma • Solid Tumor